RA Capital Management
Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, PCVX, RYTM, JANX, RNA, and represent 50.20% of Ra Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CDTX (+$111M), TSHA (+$29M), RNA (+$27M), HNGE (+$16M), TYRA (+$15M), EWTX (+$13M), JBIO (+$11M), TNGX (+$10M), GHRS (+$8.9M), OMDA (+$7.3M).
- Started 6 new stock positions in JBIO, IFRX, HNGE, TNGX, WGS, OMDA.
- Reduced shares in these 10 stocks: APGE (-$59M), ZLAB (-$47M), DAWN (-$46M), URGN (-$36M), RYTM (-$33M), ATXS (-$27M), KURA (-$26M), AVTE (-$23M), IDYA (-$22M), Iteos Therapeutics (-$22M).
- Sold out of its positions in ACRS, AVTE, ALEC, APGE, ATXS, BCYC, BIOA, BOLD, DRUG, CBLL.
- Ra Capital Management was a net seller of stock by $-288M.
- Ra Capital Management has $5.9B in assets under management (AUM), dropping by -0.87%.
- Central Index Key (CIK): 0001346824
Tip: Access up to 7 years of quarterly data
Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 63 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/s - SH (ASND) | 29.9 | $1.8B | 10M | 172.60 |
|
|
| Vaxcyte SH (PCVX) | 6.6 | $389M | 12M | 32.51 |
|
|
| Rhythm Pharmaceuticals SH (RYTM) | 5.9 | $351M | -8% | 5.6M | 63.19 |
|
| Janux Therapeutics SH (JANX) | 4.4 | $259M | 11M | 23.10 |
|
|
| Avidity Biosciences SH (RNA) | 3.5 | $206M | +15% | 7.3M | 28.40 |
|
| Arcellx SH (ACLX) | 3.4 | $200M | 3.0M | 65.85 |
|
|
| 89bio SH (ETNB) | 3.3 | $195M | 20M | 9.82 |
|
|
| Ars Pharmaceuticals SH (SPRY) | 3.2 | $190M | 11M | 17.45 |
|
|
| Newamsterdam Pharma Co Nv SH (NAMS) | 3.1 | $184M | 10M | 18.11 |
|
|
| Sionna Therapeutics SH (SION) | 3.1 | $181M | 10M | 17.35 |
|
|
| Cidara Therapeutics SH (CDTX) | 2.8 | $164M | +207% | 3.4M | 48.71 |
|
| Edgewise Therapeutics SH (EWTX) | 2.2 | $130M | +11% | 9.9M | 13.11 |
|
| Lenz Therapeutics SH (LENZ) | 2.1 | $123M | 4.2M | 29.31 |
|
|
| Wave Life Sciences SH (WVE) | 2.0 | $118M | 18M | 6.50 |
|
|
| Tyra Biosciences SH (TYRA) | 2.0 | $117M | +14% | 12M | 9.57 |
|
| Gh Research SH (GHRS) | 1.6 | $94M | +10% | 7.7M | 12.19 |
|
| Dyne Therapeutics SH (DYN) | 1.6 | $93M | 9.7M | 9.52 |
|
|
| Geron Corp SH (GERN) | 1.4 | $85M | 60M | 1.41 |
|
|
| Disc Medicine SH (IRON) | 1.4 | $84M | 1.6M | 52.96 |
|
|
| Mineralys Therapeutics SH (MLYS) | 1.4 | $83M | 6.1M | 13.53 |
|
|
| Septerna SH (SEPN) | 1.2 | $74M | 7.0M | 10.57 |
|
|
| Fulcrum Therapeutics SH (FULC) | 1.2 | $70M | 10M | 6.88 |
|
|
| Bicara Therapeutics SH (BCAX) | 1.1 | $65M | 7.0M | 9.29 |
|
|
| Vor Biopharma SH (VOR) | 1.1 | $64M | 40M | 1.62 |
|
|
| Taysha Gene Therapies SH (TSHA) | 0.9 | $54M | +116% | 24M | 2.31 |
|
| Dianthus Therapeutics SH (DNTH) | 0.9 | $53M | 2.9M | 18.63 |
|
|
| Rxsight SH (RXST) | 0.8 | $48M | 3.7M | 13.00 |
|
|
| Tourmaline Bio SH (TRML) | 0.7 | $41M | 2.5M | 15.99 |
|
|
| Scholar Rock Holding Corp SH (SRRK) | 0.7 | $40M | 1.1M | 35.42 |
|
|
| Climb Bio SH (CLYM) | 0.7 | $39M | 31M | 1.24 |
|
|
| Structure Therapeutics SH (GPCR) | 0.5 | $32M | 1.5M | 20.74 |
|
|
| Solid Biosciences SH (SLDB) | 0.5 | $28M | +34% | 5.8M | 4.87 |
|
| Metsera SH (MTSR) | 0.3 | $19M | 676k | 28.45 |
|
|
| Monopar Therapeutics SH (MNPR) | 0.3 | $18M | 511k | 35.78 |
|
|
| Nkarta SH (NKTX) | 0.3 | $18M | 11M | 1.66 |
|
|
| Larimar Therapeutics SH (LRMR) | 0.3 | $18M | 6.0M | 2.89 |
|
|
| Acumen Pharmaceuticals SH (ABOS) | 0.3 | $17M | 15M | 1.16 |
|
|
| Enliven Therapeutics SH (ELVN) | 0.3 | $17M | 849k | 20.06 |
|
|
| Travere Therapeutics SH (TVTX) | 0.3 | $17M | 1.2M | 14.80 |
|
|
| 4d Molecular Therapeutics In SH (FDMT) | 0.3 | $17M | 4.6M | 3.71 |
|
|
| Hinge Health Inc-a SH (HNGE) | 0.3 | $16M | NEW | 300k | 51.75 |
|
| Artiva Biotherapeutics SH (ARTV) | 0.3 | $15M | 9.9M | 1.51 |
|
|
| Pepgen SH (PEPG) | 0.2 | $12M | 11M | 1.11 |
|
|
| Jade Biosciences SH (JBIO) | 0.2 | $11M | NEW | 1.1M | 9.99 |
|
| Tango Therapeutics SH (TNGX) | 0.2 | $10M | NEW | 2.0M | 5.12 |
|
| Acrivon Therapeutics SH (ACRV) | 0.2 | $9.9M | 8.3M | 1.19 |
|
|
| Eledon Pharmaceuticals SH (ELDN) | 0.2 | $9.7M | 3.6M | 2.71 |
|
|
| Arcus Biosciences SH (RCUS) | 0.2 | $9.3M | 1.1M | 8.14 |
|
|
| Perceptive Capital Solutions SH (PCSC) | 0.1 | $8.0M | 750k | 10.62 |
|
|
| Omada Health SH (OMDA) | 0.1 | $7.3M | NEW | 400k | 18.30 |
|
| Werewolf Therapeutics SH (HOWL) | 0.1 | $7.3M | +8% | 6.7M | 1.09 |
|
| Beta Bionics SH (BBNX) | 0.1 | $7.3M | 500k | 14.56 |
|
|
| Cytomx Therapeutics SH (CTMX) | 0.1 | $6.0M | +166% | 2.7M | 2.27 |
|
| 10x Genomics Inc-class A SH (TXG) | 0.1 | $5.5M | -75% | 475k | 11.58 |
|
| Surrozen SH (SRZN) | 0.1 | $5.4M | -11% | 603k | 8.94 |
|
| Genedx Holdings Corp SH (WGS) | 0.1 | $5.4M | NEW | 58k | 92.31 |
|
| Avalo Therapeutics SH (AVTX) | 0.1 | $4.7M | -3% | 933k | 4.99 |
|
| Adicet Bio SH (ACET) | 0.1 | $4.6M | 7.5M | 0.61 |
|
|
| Mbx Biosciences SH (MBX) | 0.1 | $4.3M | -74% | 378k | 11.41 |
|
| Protara Therapeutic SH (TARA) | 0.1 | $3.1M | -69% | 1.0M | 3.03 |
|
| Newamsterdam Pharma Co Nv-27 SH (NAMSW) | 0.0 | $2.7M | 333k | 8.00 |
|
|
| Acadia Healthcare SH (ACHC) | 0.0 | $2.0M | -58% | 89k | 22.69 |
|
| Inflarx Nv SH (IFRX) | 0.0 | $1.6M | NEW | 2.0M | 0.79 |
|
Past Filings by Ra Capital Management
SEC 13F filings are viewable for Ra Capital Management going back to 2010
- Ra Capital Management 2025 Q2 filed Aug. 14, 2025
- Ra Capital Management 2025 Q1 filed May 15, 2025
- Ra Capital Management 2024 Q4 filed Feb. 14, 2025
- Ra Capital Management 2024 Q3 filed Nov. 14, 2024
- Ra Capital Management 2024 Q2 filed Aug. 14, 2024
- Ra Capital Management 2024 Q1 amended filed May 17, 2024
- Ra Capital Management 2024 Q1 filed May 15, 2024
- Ra Capital Management 2023 Q4 filed Feb. 14, 2024
- Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
- Ra Capital Management 2023 Q3 filed Nov. 14, 2023
- Ra Capital Management 2023 Q2 filed Aug. 14, 2023
- Ra Capital Management 2023 Q1 filed May 15, 2023
- Ra Capital Management 2022 Q4 filed Feb. 14, 2023
- Ra Capital Management 2022 Q3 filed Nov. 14, 2022
- Ra Capital Management 2022 Q2 filed Aug. 15, 2022
- Ra Capital Management 2022 Q1 filed May 16, 2022